Gynecologic Cancer Central

Despite the incidence of endometrial cancer diagnosis increasing annually, several promising approaches for treatment and diagnosis of endometrial cancer have been approved or are in development.

Healio spoke with Naoko Sasamoto, MD, MPH, from the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Harvard Medical School, about her JAMA Oncology study that suggested breastfeeding as a potentially modifiable factor that may decrease risk for ovarian cancer independent of pregnancy alone – and what this means for clinicians.

Researchers are preparing to launch a phase 3 trial evaluating a dendritic cell-based immunotherapy known as DCVAC after phase 2 data showed the addition of DCVAC to chemotherapy significantly improved OS among women with ovarian carcinoma.

Jayanthi Lea, MD, FACOG, FACS, Patricia Duniven Fletcher Distinguished Professorship in Gynecological Oncology, associate professor of gynecologic oncology and program director for gynecologic oncology at UT Southwestern Medical Center, spoke with Healio about genetic variants linked to ovarian cancer, how the identification of these variants changed prevention and treatment strategies, and updated guidance on genetic testing that physicians should be aware of and share with their patients.

Healio spoke with Jerome Strauss III, MD, PhD, professor of obstetrics and gynecology at Virginia Commonwealth University, emeritus professor of obstetrics and gynecology at Perelman School of Medicine, University of Pennsylvania, and chair of the Committee on the State of the Science in Ovarian Cancer Research, about the committee’s 2016 report on paradigm shifts in research and care, changes in the field since the report, and important areas that need more attention.